Status:
UNKNOWN
Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.
Lead Sponsor:
St. Petersburg State Pavlov Medical University
Conditions:
Cardiac Procedure Complication
Ischemic Heart Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.
Detailed Description
To assess outcomes after cardiac surgery procedures. To investigate serum level of myeloperoxidase, morphology of left atrium appendage, to perform genetic analysis and cell biology.
Eligibility Criteria
Inclusion
- ischemic heart disease with indications for operation
- valve disease with indications for operation
- ischemic heart disease combined with valve disease with indications for operation
Exclusion
- patient refusal
Key Trial Info
Start Date :
December 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03786965
Start Date
December 20 2018
End Date
December 20 2025
Last Update
November 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nikolai Bunenkov
Saint Petersburg, Non-US/Non-Canadian, Russia, 194358